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Abstract: 4-Hydroxynonenal (HNE) is a major aldehydic product of lipid peroxidation known to
exert several biological effects. Normal and malignant cells of the same origin express different
sensitivity to HNE. We used human osteosarcoma cells (HOS) in different stages of differentiation
in vitro, showing differences in mitosis, DNA synthesis, and alkaline phosphatase (ALP) staining.
Differentiated HOS cells showed decreased proliferation (3H-thymidine incorporation), decreased
viability (thiazolyl blue tetrazolium bromide-MTT), and increased apoptosis and necrosis (nuclear
morphology by staining with 4′,6-diamidino-2-phenylindole-DAPI). Differentiated HOS also had
less expressed c-MYC, but the same amount of c-FOS (immunocytochemistry). When exposed to
HNE, differentiated HOS produced more reactive oxygen species (ROS) in comparison with undiffer-
entiated HOS. To clarify this, we measured HNE metabolism by an HPLC method, total glutathione
(GSH), oxidized GSH (ox GSH), glutathione transferase activity (GST), proteasomal activity by en-
zymatic methods, HNE-protein adducts by genuine ELISA and fatty acid composition by GC-MS
in these cell cultures. Differentiated HOS cells had less GSH, lower HNE metabolism, increased
formation of HNE-protein adducts, and lower proteasomal activity, in comparison to undifferentiated
counterpart cells, while GST and oxGSH were the same. Fatty acids analyzed by GC-MS showed that
there is an increase in C20:3 in differentiated HOS while the amount of C20:4 remained the same.
The results showed that the cellular machinery responsible for protection against toxicity of HNE was
less efficient in differentiated HOS cells. Moreover, differentiated HOS cells contained more C20:3
fatty acid, which might make them more sensitive to free radical-initiated oxidative chain reactions
and more vulnerable to the effects of reactive aldehydes such as HNE. We propose that HNE might
act as natural promotor of decay of malignant (osteosarcoma) cells in case of their differentiation
associated with alteration of the lipid metabolism.
Keywords: 4-hydroxynonenal; human osteosarcoma; differentiation; proliferation; apoptosis; ALP;
GSH; GST; proteasomal activity; HNE-protein adducts; fatty acid; C20:3
1. Introduction
Oxidative stress occurs in cells as a consequence of oxygen metabolism. The reactive
oxygen species (ROS) produced during oxidative stress may damage intracellular compo-
nents, including lipids causing chain reaction of lipid peroxidation. Reactive aldehydes,
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end-products of lipid peroxidation, are involved in the onset and progression of many
diseases such as cardiovascular diseases, neurodegeneration, fibroproliferative disorders,
cancer, etc. [1–3]. Unregulated or prolonged production of ROS as well as of reactive alde-
hydes may influence cancer development and progression not only directly as a mutagen
but also through modification of gene expression [4]. Tumor cells are under persistent
mild oxidative stress which seems to be beneficial for them, increasing their metastatic
potential and genetic instability, thus helping tumor cells to survive and progress [5,6].
It is well documented that antioxidant defense systems are altered in tumorigenesis pro-
moting tumor progression [7]. On the other hand, severe oxidative stress is harmful for
tumor cells; additional ROS production caused by chemotherapy, irradiation, or innate
immune response is cytotoxic and leads to cellular destruction [1,8]. Nowadays, numerous
strategies in cancer therapy rely on inducing excessive ROS, promoting lipid peroxidation
and ferroptosis [9]. Osteosarcoma cells are often resistant to oxidative stress induced by
chemotherapy [10,11].
The focus of our research is differences in response of differentiated and undifferenti-
ated cells to lipid peroxidation, in particular with respect to the role of second messenger of
ROS 4-hydroxynonenal (HNE). HNE alters cellular functions such as membrane integrity,
mitochondrial respiration, etc.; but it is also a signaling molecule modulating expression of
stress genes [4,12].
Normal and malignant cells of the same origin differ in sensitivity to oxidative stress.
We have previously described differential sensitivity to HNE of CEM-NKR leukemic cells
and normal human peripheral mononuclear cells, where HNE inhibited the growth of ma-
lignant cells, but not normal [13]. The same result is observed when normal and malignant
mesenchymal cells are analyzed. Normal human osteoblasts and WI38 fibroblasts are less
sensitive to HNE than 143 B and HOS osteosarcoma cells [14]. In this article we wanted
to clarify whether differentiation of the mesenchymal cells would influence sensitivity to
HNE. HOS cell line is able to differentiate in cell culture, so it is used for this purpose [15].
We analyzed HOS cells with different degrees of differentiation in respect to their sensitiv-
ity to HNE, ability to detoxify HNE, GSH content, GST activity, and proteasomal activity.
We also analyzed the composition of fatty acids in those cells as they serve as a substrate
for oxidation, increasing the damage to the cells.
2. Materials and Methods
2.1. HOS Cell Line
The human osteosarcoma cell line HOS was obtained from American Type Culture
Collection (ATCC). Cells were maintained in DMEM (Dulbecco’s modified eagle’s medium,
Sigma-Aldrich, St. Louis, MO, USA) with 5% (v/v) fetal calf serum (FCS, Sigma-Aldrich,
St. Louis, MO, USA) in T75 cell culture flasks (Sarstedt, Nümbrecht, Germany), in an incuba-
tor (Heraeus, Hanau, Germany) at 37◦C, with a humid air atmosphere containing 5% CO2.
For the experiments, cells were detached from semiconfluent cultures with a 0.25% (w/v)
trypsin solution for 5 min. Viable cells (upon trypan blue exclusion assay) were counted on
a Bürker-Türk hemocytometer and used for experiments. All cell culture experiments were
performed in such conditions if not stated otherwise for each particular experiment.
In order to differentiate the HOS cell culture, cells were grown for 10 days without
detaching and medium was changed every second day. After this period, cells were used
for experiments, and are referred as differentiated HOS. Likewise, HOS cells which were
maintained in semiconfluent state are referred as undifferentiated HOS.
2.2. Alkaline Phosphatase Staining
Undifferentiated and differentiated HOS were washed with phosphate buffered saline
(PBS) pH 7, fixed with 4% buffered paraformaldehyde (Kemika, Zagreb, Croatia) for 1 h at
4 ◦C. Before staining cells were washed three times with PBS and three times with 0.9%
NaCl. Cells were then incubated with 500 µL/cm2 of stain (naphthol phosphate AsMx
(Sigma-Aldrich, St. Louis, MO, USA), 4.4 mg sodium borate (Kemika, Zagreb, Croatia),
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0.9 mg Fast Blue RR (Sigma-Aldrich, St. Louis, MO, USA), 36 µg magnesium sulphate
(Kemika, Zagreb, Croatia) in 1 mL of 0.9% NaCl (Kemika, Zagreb, Croatia) pH 8.5) at
37 ◦C for 30 min in incubator (Heraeus, Hanau, Germany). Cells of osteogenic origin have
alkaline phosphatase (ALP) which increase with cell differentiation [15,16]. Yellow stain
was metabolized to blue deposits if ALP was present in cells. Number of ALP-positive
nodules was counted in cell cultures.
2.3. 3H-Thymidine Incorporation Assay
The rate of radioactive 3H-thymidine incorporation into DNA was used to measure
proliferative activity of differentiated and undifferentiated HOS. Differentiated and undif-
ferentiated HOS were detached, seeded 2 × 104 cells in 96-well microtiter plates (Greiner
Bio-One GmbH, Frickenhausen, Germany) in a final volume of 200 µL and were cultured
for 48 h. For testing effects of HNE on cell proliferation, HOS were treated with different
concentrations of HNE (0, 1, 5, or 10 µM) for 48 h. After the first 24 h 0.1 µCi of radioactive
thymidine ([6-3H] thymidine, 1 mCi/mL, Amersham Biosciences, Amersham, UK) was
added to each well. The cells were harvested on glass filters in a cell harvester (Skatron,
Lier, Norway) and 3H-thymidine incorporation was measured using a liquid scintillation
β-counter (Beckman 7400, Brea, CA, USA) [15].
2.4. GSH Measurement
Differentiated and undifferentiated HOS were detached, washed with PBS and frozen
immediately in liquid nitrogen. Total and oxidized glutathione were determined by method
of Teitze [17]. Briefly, 1 × 106 cells were resuspended in 50 µL of 0.1 M phosphate buffer
with 5 mM EDTA, pH 7.5. Next, 5 µL of such sample was resuspended in 250 µL of
phosphate buffer, vortexed, centrifuged for 7 min at 500× g and supernatant was taken
for analysis. GSH standards were prepared from freshly prepared 1 mM GSH (Sigma-
Aldrich, St. Louis, MO, USA) stock solution. A total of 10 µL of standards and samples
were pipetted to 96-microwell plates with 50 µL phosphate buffer and background ab-
sorbance was measured at 415 nm (Easy-Reader 400 FW, SLT Lab Instruments GmbH,
Salzburg, Austria). After that, 50 µL of 0.948 mg/mL DTNB (5,5’-dithio-bis-2-Nitrobenzoic
Acid, Sigma-Aldrich, St. Louis, MO, USA), 50 µL of glutathione reductase, 8 U/mL and
0.667 mg/mL NADPH were added. The reaction mix was incubated for 3 min at room
temperature, when absorbance was measured at 415 nm. The cellular GSH content was
calculated from the standard curve. The same cell lysates were used for determination of
oxidized GSH. The procedure was the same, only with 0.02 M NEM (N-ethylmaleimid,
Sigma-Aldrich, St. Louis, MO, USA) in phosphate buffer used in the second step cells were
resuspended. NEM blocks free GSH and leaves only oxidized GSH in cell sample [17].
The amount of GSH was calculated according to amount of cellular proteins determined
by Bradford assay [18].
2.5. GST Activity
Differentiated and undifferentiated HOS were detached, washed with PBS, and frozen
immediately in liquid nitrogen. GST was determined by enzymatic method [19]. Samples
of 1× 106 cells were lysed with 500 µL of distilled water by vortexing for 2 min. Cell lysates
were centrifuged at 500× g for 7 min and supernatant was used for analysis. In total, 25 µL
of sample or GST (Sigma-Aldrich, St. Louis, MO, USA) standards were added into plastic
cuvette followed by 750 µL of 100 mM KH2PO4 (Kemika, Zagreb, Croatia) pH 6.25 and
incubated at room temperature for 5 min. Background absorbance was measured at 340 nm
(Shimatzu, Kyoto, Japan). Then, 100 µL of 7.5 mM 1-choloro-2,4-dinitrobenzene (CDNB,
Sigma-Aldrich, St. Louis, MO, USA) was added immediately followed by 100 µL of 10 mM
GSH (Sigma-Aldrich, St. Louis, MO, USA). Samples were incubated at room temperature
for 15 min and second absorbance was measured at 340 nm. First absorbance was taken
from the second one and results were calculated from standard curve. The amount of GST
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activity was calculated according to amount of cellular proteins determined by Bradford
assay [18].
2.6. Cell Viability Assay
Thiazolyl blue tetrazolium bromide (MTT) was used to measure mitochondrial activity
which reflects viability of the cells. Differentiated and undifferentiated HOS were detached;
the cells were plated at density of 2 × 104/well in quadruplicates into 96-microwell plates
(Greiner Bio-One GmbH, Frickenhausen, Germany) in final volume of 200 µL/well and
incubated for 24 h in DMEM with 5% of FCS containing different concentrations of HNE
(0, 1, 2.5, 5, 10, or 20 µM). After 24 h, the medium was removed and replaced with 200 µL
of Hank’s balanced salt solution without phenol red and 20 µL of the MTT substrate
solution (EZ4U, Biomedica, Vienna, Austria). Cells were incubated at 37 ◦C for 2 h and the
absorbance was measured at 450 nm with 620 nm as a reference wavelength [20] on a plate
reader (Easy-Reader 400 FW, SLT Lab Instruments GmbH, Worgl, Austria).
2.7. Cell Treatments with HNE for Free HNE Analysis, GSH Analysis, and HNE-ELISA Analysis
Undifferentiated and differentiated HOS were detached, cells were washed twice
with sterile Krebs-Henseleit buffer, and suspension of 1 × 106 cells/mL was pipetted into
sterile glass tubes. Cells were then treated with HNE at final concentration of 20 µM
(20 nmol/106 cells) and incubated at 37 ◦C in incubator for 120 min unless specified
differently. This particular HNE:cells ratio was chosen because it corresponds to 2 µM
HNE in experiments in microwell plates we used through this work.
For cell viability by Trypan blue exclusion assay, cells were centrifuged at 200× g for
5 min (Heraeus, Hanau, Germany), the supernatants were discarded, and cell viability was
determined immediately by Trypan blue.
For free-HNE analysis, samples were taken at different time points (30, 60, 90, and 120 min),
and centrifuged at 200× g for 5 min (Heraeus, Hanau, Germany). The supernatants were
mixed with an equal volume of acetonitrile/acetic acid (24:1 v:v, (Merck, Darmstadt,
Germany), centrifuged, and the supernatants were further stored at −80 ◦C for free HNE
analysis on HPLC.
For the HNE-ELISA (HNE-binding studies), cells were centrifuged at 200× g for 5 min
(Heraeus, Hanau, Germany) the supernatants were discarded, and the cell pellets were
washed twice with PBS, centrifuged, and stored at −80 ◦C till analyses.
For the GSH analysis, cells were centrifuged at 200× g for 5 min (Heraeus, Hanau,
Germany), the supernatants were discarded, and the cell pellets were washed twice with
PBS, centrifuged, and stored at −80 ◦C till the analyses.
2.8. Determination of Free HNE by HPLC Method
HNE standards were prepared by serial dilution from 1M HNE stock solution stored
at −20 ◦C. Samples stored at −80 ◦C where thawed prior to analysis. After thawing,
samples were vortexed, centrifuged at 500× g 20 min at 4 ◦C (Sigma Laborzentrifugen
GmbH, Osterode am Harz, Germany) and analyzed by HPLC as already described [21].
The samples (20 µL) were injected into the HPLC system (Beckman System Gold Solvent
module 128 with the UV Detector, Beckman, Brea, CA, USA and a Midas Spark Holland
autosampler, Spark Holland, Emmen, The Netherlands). The mobile phase consisted
of acetonitrile/water (42:58, v/v) (Merck, Darmstadt, Germany). The flow was set to
0.9 mL/min and the absorbance at 223 nm. The samples were analyzed on a Beckman
Ultrasphere ODS, 5 µm, 4.6 × 150 mm column (Beckman Coulter, Brea, CA, USA) at
room temperature.
2.9. Determination of HNE-Protein Adducts by HNE-ELISA
Cell pellets were lysed with 400 µL of lysis buffer (6M guanidine, 0.6055 g TRIS,
0.8766 g NaCl in 100 mL H2O, pH 7.5 with 1% (v/v) Triton X-100, 2% (w/v) sodium
deoxycholate and 2% (w/v) SDS; all Sigma-Aldrich, St. Louis, MO, USA) and immediately
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before use, phenylmethylsulfonyl fluoride (PMSF, Sigma-Aldrich, St. Louis, MO, USA)
was added to reach final concentration of 1 mM per 1 × 106 cells. The lysates were set to
concentration of 5 × 104 cells in 20 µL. Samples were analyzed by the ELISA as described
before [21]. The results obtained in the experiments are expressed as nmol of HNE-His/mg
of proteins.
2.10. Analysis of Nuclear Morphology with 4′,6-diamidino-2-phenylindole
Cells were prepared the same way as for MTT assay and plated on an 8-well Nunc
chamber slide (Sigma, St. Louis, MO, USA). Differentiated and undifferentiated HOS
were treated with different concentrations of HNE (0, 1, 5, or 10 µM) as described above.
After 24 h cells were fixed with 4% formaldehyde. Cells were then incubated with 0.3 µM
4′,6-diamidino-2-phenylindole (DAPI) solution in PBS for 5 min, rinsed with distilled
water, and air-dried in the dark. Slides were mounted with glycerol and were scored
blind for gross nuclear morphology under fluorescence microscope (Zeiss Axiovert25,
HBO 50 Oberkochen, Germany). Morphology evaluation included scoring for nucleus
size, chromatin condensation (condensation of chromosomes and necrotic shrinkage of
chromatin), and presence of micronuclei, providing information about cell cycle phases,
apoptosis, and necrosis, as described before [15,22].
2.11. ROS Measurement
Cellular ROS production was measured by a method based on oxidation of 2,7-
dichlorodihydrofluorescein diacetate (DCFH-DA, Fluka, Charlotte, NC, USA) to the fluores-
cent compound 2,7-dichlorofluorescein (DCF). This probe is highly reactive with hydrogen
peroxide and has been used to evaluate ROS generation in cells [23,24]. HOS cells were
seeded in white 96-well plates at density of 2 × 104 cells per well in DMEM supplemented
with 5% FCS 2 h prior to treatment. After 2 h, medium was removed, the cells were washed
with Hanks balanced salt solution (HBSS) and incubated with 10µM DCFH-DA in the
HBSS. After DCFH-DA was removed, the cells were washed and incubated with HBSS
buffer with different concentrations of HNE (0, 1, 2.5, 5, or 10 µM HNE) for 2 h and the
fluorescence intensity was measured with a Varian fluorescence spectrophotometer (Varian,
Palo Alto, CA, USA) with an excitation wavelength of 500 nm and emission detection
at 529 nm and under fluorescence microscope (Zeiss Axiovert25, HBO 50, Oberkochen,
Germany). Results are expressed as relative fluorescence units (RFU).
2.12. Immunocytochemical Fluorescence Labeling for c-FOS and c-MYC
Cells were prepared the same way as for MTT assay and plated on an 8-well Nunc
chamber slide (Sigma, St. Louis, MO, USA) and left to attach for 6 h. Differentiated
and undifferentiated HOS were treated with different concentrations of HNE (0, 1 µM)
as described above. After 24 h cells were fixed 2 min with methanol and stored in 4%
buffered formaldehyde until analysis. Samples were washed 3 × 5 min with PBS before
immunocytochemistry.
C-MYC immunostaining was performed with primary antibody against c-MYC (SC-42
Santa Cruz Biotechnology, Dallas, TX, USA) diluted 1:50 with 1% of bovine serum albumin
(BSA) in PBS incubated overnight at±4 ◦C. After that, samples were washed with 3× 5 min
with PBS and overlaid with secondary antibody labelled with Texas red (TR, sc 3797 Santa
Cruz Biotechnology, Dallas, TX, USA) diluted 1:100 in 1% BSA with PBS for 2 h. Samples
were washed 3 × 5 min with PBS, mounted in glycerol, and analyzed under fluorescence
microscope (Zeiss Axiovert25, HBO 50, Oberkochen, Germany) with ImageJ software (NIH
and LOCI, Bethesda, WI, USA). Results are expressed as fluorescence intensity.
C-FOS immunostaining was performed with primary antibody against c-FOS (F7799
Sigma-Aldrich, St. Louis, MO, USA) diluted 1:100 with 1% of bovine serum albumin (BSA)
in PBS incubated overnight at ±4 ◦C. After that, samples were washed with 3 × 5 min with
PBS and overlaid with secondary antibody labeled with fluorescein isothiocyanate (FITC,
F1262 Sigma, St. Louis, MO, USA) diluted 1:100 in 1% BSA with PBS for 2 h. Samples
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were washed 3 × 5 min with PBS, mounted in glycerol and analyzed under fluorescence
microscope (Zeiss Axiovert25, HBO 50, Oberkochen, Germany) with ImageJ software (NIH
and LOCI, Bethesda, WI, USA). Results are expressed as fluorescence intensity.
2.13. Proteasomal Activity
Cells were grown in T25 cell culture flasks (Sarstedt, Nümbrecht, Germany), trypsinized,
centrifuged 5 min at 200× g, and supernatant was discarded. Cell pellets were resuspended
in 200 µL cold (4 ◦C) lysis buffer (250 mM saccharose, 25 mM HEPES, 10 mM MgCl2, 1 mM
EDTA, pH 7.8 with 1 mM dithiothreitol, DTT, Carl Roth, Karlsruhe, Germany) and lysed
on shaker at highest speed for 1 h at 4 ◦C. Samples were then centrifuged for 30 min at
3000× g at 4 ◦C. Supernatants were used for determination of 26S proteasomal activity.
Reaction mix consisted of 10 µL of sample; 33.3 µL of incubation buffer (450 mM TRIS,
90 mM KCl, 15 mM Mg-acetate, 15 mM Mg-chloride, pH 8.2); 0.2 µL of 0.5 M DTT; 61.5 µL
of H2O, 4.5 µL 531 µM Lactacystin (Sigma-Aldrich, St. Louis, MO, USA). Reaction mix
was left for 10 min, and then 5 µL of 100 mM ATP and 10 µL of 2 mM Suc-LLVY-MCA
(Bachem, Bubendorf, Switzerland) fluorogenic peptide substrate was added. Standards
were prepared by dissolving 7-Amino-4-methylcoumarin (MCA, Sigma-Aldrich, St. Louis,
MO, USA). Reaction was then incubated in dark at 37 ◦C 30–60 min. Results were analyzed
by plate reader fluorometer with λex 360 nm and λem 460 nm [25].
2.14. Fatty Acid Analysis
For the analysis of fatty acid composition, undifferentiated and differentiated HOS
were grown in flasks and triplicates of two different cultures were prepared. Cells were
trypsinized, washed, counted, and 1× 107 cell was used for fatty acid analyses. Lipids were
extracted in chloroform:methanol (2:1) according to Folch [26]. Heptadecanoic acid C17:0
was added as an internal standard (IS). Fatty acid methyl esters (FAME) were prepared
by transesterification with 14% (v/v) boron trifluoride and dissolved in petroleum ether.
Fatty acid methyl esters were analyzed with GC-MS, using a Trace GC and a DSQ mass
spectrometer (Thermo, San Jose, CA, USA). Separation was performed on a DB-5MS
column (60 m, ID 0.32 mm, 0.25 µm film thickness) (Agilent, Waldbronn, Germany), helium
was used as carrier gas and a temperature gradient from 130 to 250 ◦C within 50 min was
applied. Data analysis was done with Xcalibur 1.4 software (Thermo, San Jose, CA, USA)
and the NIST library for spectrum identification [27,28].
2.15. Statistical Analysis
All assays were carried out in triplicates unless otherwise stated for each particular
method. The comparison of the mean values was done using Student’s t-test considering
values of p < 0.05 as significantly different.
3. Results
3.1. Characterization of Undifferentiated and Differentiated HOS
Differentiated and undifferentiated HOS cells stained for the presence of alkaline phos-
phatase (ALP) are presented in Figure 1A,B. Undifferentiated HOS cell cultures (Figure 1A)
were not stained blue indicating lack of ALP activity. Differentiated HOS cell cultures
(Figure 1B) showed blue nodules, which indicated presence of ALP activity.
DAPI staining of differentiated and undifferentiated HOS are presented in Figure 1C,D.
Undifferentiated HOS cell cultures (Figure 1C) had high numbers of mitotic cells and pres-
ence of these cells is indicated by pink arrows, while differentiated HOS cell cultures had
low numbers of mitotic cells. Differentiated and undifferentiated HOS cells are different
(Table 1) with respect to the number of alkaline phosphatase positive nodules in cell culture
(p < 0.0002), mitosis (p < 0.001), and 3H-thymidine incorporation (p < 0.05). Apoptotic cells
were not detected in either of the cell cultures.
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sented in Figure 2D. Differentiated HOS had lower proteasomal activity than undifferen-
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Figure 1. Differentiated and undifferentiated HOS: alkaline phosphatase staining of (A) undifferentiated HOS and (B) differ-
entiated HOS (blue staining of nodules indicate alkaline phosphatase positive cells); DAPI staining of (C) undifferentiated
HOS and (D) differentiated HOS (arrows point to the mitotic cells).
Table 1. Characterization of undifferentiated and differentiated cell cultures.
Mitosis Apoptosis ALP Positive Nodules/10 cm2 3H-Thymidine
Undifferentiated HOS 23% 0% 0.74 ± 0.64 17,698 ± 1230
Differentiated HOS 3% 0% 37.77 ± 4.84 9814 ± 920
t-test p < 0.001 p < 0.0002 p < 0.05
3.2. GSH, ox GSH, GST, and Proteasomal Activity in Undifferentiated and Differentiated HOS
Total glutathione (GSH) content in cell cultures expressed in nmol/mg of cellular
proteins is presented in Figure 2A. Differentiated HOS contained lower amount of GSH
than undifferentiated HOS (p < 0.05). Content of oxidized GSH in cell cultures is presented
in Figure 2C. Both cell cultures had level of oxidized glutathione below 10% of total
GSH and it was not different between undifferentiated and differentiated HOS (p > 0.05).
Glutathione transferase (GST) activity expressed in U/mg of cellular proteins is presented in
Figure 2B. Undifferentiated and differentiated HOS cell cultures had the same GST activity
(p > 0.05). Proteasomal activity was calculated as activity in µmol/(mg*min) and presented
in Figure 2D. Differentiated HOS had lower proteasomal activity than undifferentiated
HOS (p < 0.05).
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undiff rentiated HOS treated with 1 µM HNE, di ferentiate fi tl lo er
viability hen treated ith 2.5 µ , 5 µM, and 10 µM HNE (p < 0.05).
r lif r ti f treate it dif erent concentrati s of is presented in
i re 3B. Si ilarly to cell viability assay, both undifferentiated and differentiated HOS
treated with 1 µM HNE did not show any differences when compared to control, untreated
cells nor compared to each other (p > 0.05). Higher concentrations of HNE (5 µM, 10 µ )
significantly decreased proliferation in both, undifferentiated and ifferentiated HOS
compared to the control (p < 0.05). Treatment with 5 µM HNE significantly decreased prolif-
eration of differentiated HOS compared to undifferentiated HOS (p < 0.05). Treatment with
10 µM HNE completely blocked proliferation of both undifferentiated and differentiated
HOS (p > 0.05).
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Effects of different concentrations of HNE on distribution of different phases of cell
cycle ar presented in Figure 3B. In control cultures, undifferentiated HOS cells had high
number of mitosis (22 ± 4%). Control cultures of differentiat d HOS cells recovered mitotic
activity when trypsinized and plated at low density (20 ± 6%). While undiff rentiated
HOS were slightly stimulated by 1 µM HNE, ifferentiated HOS significantly d cre s
mitotic index (6 ± 3%, p < 0.05), had similar reaction pattern as treatment wi h 5 µM HNE
(mitotic index 3 4%, apoptosis 6 ± 6%, necrosis 14 ± 10%). Unlike differentiated OS,
undifferentiated HOS treated with 5 µM HNE had higher mitotic index (11 ± 3%) and
lower p rcentage of necrotic cells (2 ± 1%). Fin lly, w ile treatment with 0 µM HNE
caused necrosis of diff rentiated HOS, undifferentiated HOS h d 21 ± 5% apoptosis and
16 ± 6% necro is/late apoptosis.
3.4. HNE Metabolism, GSH Content, Formation of HNE-Protein Adducts
Effects of concentration of HNE 20 nmol/106 cells n HNE me abolism, GSH content,
formation of HNE-protein adducts, and cell viability in undifferentiated and differentiated
HOS cell cultures are presented in Figure 4.
Cells 2021, 10, 269 10 of 20
Cells 2020, 9, x 10 of 20 
 
 
Figure 4. Treatment of undifferentiated and differentiated HOS with HNE (20 nmol/106 cells). (a) elimination of HNE from 
the media; (b) content of GSH in cells treated with HNE; (c) amount of HNE-protein adducts in cell cultures treated with 
HNE; (d) cell viability checked through the time of experiment upon trypan blue exclusion assay. Difference according to 
t-test significant between two cultures, * p < 0.05. 
Free HNE in cell cultures supernatants is presented in Figure 4A. Undifferentiated 
and differentiated HOS decreased initial HNE concentration already after 30 min (p < 0.05 
for both cultures). Undifferentiated HOS were more efficient in decreasing free HNE to 
40% of initial value after 120 min (p < 0.05) while in the same period differentiated HOS 
decreased HNE to 60% of initial value (p < 0.05). Kinetic of GSH in undifferentiated and 
differentiated cell cultures after treatment with HNE are presented in Figure 4B. GSH de-
creased during observed period of 120 min in both undifferentiated and differentiated 
HOS (p < 0.05). Concentration of GSH remained higher in undifferentiated cells through-
out the observed period of 90 min (p < 0.05). HNE-protein adducts formed after treatment 
with HNE are presented on Figure 4C. In undifferentiated HOS cells HNE-protein ad-
ducts increased until 30 min when they reached plateau, while in differentiated HOS the 
plateau was reached after 60 min. Amount of HNE-protein adducts in differentiated HOS 
cell cultures was higher than in undifferentiated (p < 0.05). Cell viability evaluated upon 
trypan blue exclusion assay presented in Figure 4D shows that both undifferentiated HOS 
and differentiated HOS were viable throughout the whole experiment, (p > 0.05). 
3.5. ROS Production in Cells after Treatment with HNE 
ROS production in undifferentiated and differentiated HOS 2 h after treatment with 
different concentrations of HNE (0, 1, 2.5, 5, and 10 µM) is presented in Figure 5. Green 
fluorescence indicated presence of ROS in cell cultures. HNE caused concentration-de-
pendent increase in ROS production in both cell cultures (p < 0.05 for 5 and 10 µM HNE). 
More ROS was present in differentiated HOS cell cultures (p < 0.05 for 5 and 10 µM HNE).  
Figure 4. reatment of undif erentiated and differentiated HOS with HNE (20 nmol/106 cel s). (a) eli ination of E from
the media; (b) content of GSH in cel s treated with HNE; (c) amount of HNE-protein adducts in cel cultures treated with
HNE; (d) cell viability checked through the ti e of experi ent upon trypan blue exclusion assay. Difference according to
t-test significant between two cultures, * p < 0.05.
Free HNE in cell cultures supernatants is present d in Figure 4A. Undifferentiated nd
differentiated HOS decreased initial HNE concentration already fter 30 min (p < 0.05 for
b th cultures). Undifferentiated HOS were mo efficient in decreasing free HNE to 40% of
initial value fter 120 min (p < 0.05) while in the same period differentiated HOS decreased
HNE to 60% of initial value (p < 0.05). Kinetic of GSH in undifferent ated and differentiated
cell cultures after trea ment with HNE are presented in Figure 4B. GSH dec ased during
observed period of 120 min in both undiffere tiated a differen iated HOS (p < 0.05).
Concentration of GSH remained higher in undifferentiated cells th oughout the observed
period of 90 min (p < 0.05). HNE-protein adducts formed after treatment with HNE are
presented on Figure 4C. In u differentiated HOS cells HNE-protein adducts increased until
30 min wh n they reached plateau, w ile in differentiated HOS the plat au w s reached af-
ter 60 min. Amount of HNE-protein add cts in differentiated HOS cell cultures was higher
than in ndifferentiated (p < 0.05). Cell viability evaluated upon trypan blue exclusion
assay presented in Figure 4D shows that both undifferentiated HOS and differentiated
HOS were viable throughout the whole experiment, (p > 0.05).
3.5. ROS Production in Cells after Treatment with HNE
ROS production in undifferentiated and differentiated HOS 2 h after treatment with
different concentrations of HNE (0, 1, 2.5, 5, and 10 µM) is presented in Figure 5. Green flu-
orescence indicated presence of ROS in cell cultures. HNE caused concentration-dependent
increase in ROS production in both cell cultures (p < 0.05 for 5 and 10 µM HNE). More ROS
was present in differentiated HOS cell cultures (p < 0.05 for 5 and 10 µM HNE).
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3.6. c-FOS and c-MYC in Undifferentiated and Differentiated HOS
Immunocytochemical fluorescent staining for c-FOS and c-MYC is presented in
Figure 6. There is no difference in the intensity of c-FOS staining in control cultures
for differentiated and undifferentiated HOS (p > 0.05). The intensity of c-FOS positivity is
the same in both cultures, differentiated and undifferentiated HOS when treated with 1 µM
HNE (p > 0.05). Unlike c-FOS, undifferentiated HOS have higher c-MYC positivity in both
control and HNE treated cultures compared to differentiated HOS (p < 0.05). C-MYC posi-
tivity decreased in undifferentiated HOS when treated with 1 µM HNE (p < 0.05).
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determined by GC-MS in cell culture samples are presented in Table 2. The most abundant 
fatty acids were palmitic acid C16:0, oleic acid C18:1, and stearic acid C18:0, although they 
did not significantly differ between two cultures (p > 0.05 for all). We observed very small 
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Figure 6. Representative i unofluorescence labeling for c-FOS and c- YC in differentiated and undifferentiated OS.
Difference according to t-test significant between two cultures, * p < 0.05; and 0 and 1 µM HNE, ** p < 0.05.
3.7. Fatty Acids Composition in Undifferentiated and Differentiated HOS
Samples of fatty acids chromatograms of undifferentiated and ifferentiated HOS
cell cultures separated by GC are presented in Figure 7. Differentiated cell cultures have
one peak higher and this was designated on a chromatogram. Based on the obtained data,
peaks eluting at the selected retention times were further analyzed by the MS. Fatty acids
determined by GC-MS in cell culture samples are presented in Table 2. The most abundant
fatty acids were palmitic acid C16:0, oleic acid C18:1, and stearic acid C18:0, although
they did not significantly differ between two cultures (p > 0.05 for all). We observed very
small amounts of C18:2 in both undifferentiated and differentiated HOS as three peaks (RT
19.52, 19.64, 19.71 min), but exact structures we could not determine so those data are not
presented in the table.
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Figure 7. Representative GC chromatograms of atty acids extracted from (a) undifferentiated HOS and (b) differentiated
HOS cell culture. Fatty acids detected in HOS are labeled on chromatograms. Dif erences in chromatographs are extracted
for each sample.
Table 2. Fatty acids detected in cell samples. Values are expressed as a percentage of IS ± sd. Difference according to t-test
significant between two cultures, * p < 0.05.
Fatty Acid Undifferentiated HOS Differentiated HOS
C14:0 Myristic acid (Tetradecanoic acid) 3.03 ± 0.72 3.57 ± 1.27
C16:0 Palmitic acid (Hexadecanoic acid) 74.01 ± 14.45 85.41 ± 32.26
C16:1 Palmitoleic acid (9-hexadecenoic acid) 10.00 ± 3.58 11.56 ± 5.01
C17:0 1 Margaric acid (Heptadecanoic a id)
C18: Oleic acid (9-Octadecenoic acid) 70.88 ± 21.05 108.37 ± 47.25
C18:0 Stearic acid (Octadecanoic acid) 40.72 ± 11.56 59.75 ± 20.63
C20:4 Arachidonic acid (5,8,11,14-Eicosatetraenoic acid) 14.29 ± 4.75 20.11 ± 9.15
C20:3 Mead acid (5,8,11-Eicosatrienoic acid) 5.40 ± 1.65 24.40 ± 10.50 *
C22:6 (4,7,10,13,16,19-Docosahexaenoic acid) 4.33 ± 1.86 6.13 ± 3.07
1 Fatty acid added to samples as IS.
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In agreement with the initial screening performed by GC-FID one fatty acid was found
to significantly differ between differentiated and undifferentiated HOS cells (Figure 8).
Differentiated HOS cells have significantly increased level of 5,8,11-eicosatrienoic acid
C20:3 n-9 (p < 0.05). The amounts of other fatty acids were not different between cultures
(p > 0.05).
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4. Discussion
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Firstly, we performed MTT assay and 3H-thymidine proliferation assay which,
surprisingly, showed that differentiated HOS are more sensitive to HNE. They also had
more apoptotic cells and late apoptotic/necrotic cells than undifferentiated HOS. Furthermore,
we made immunostaining HOS cells for the two transcription factors, c-FOS and c-MYC.
The results of c-FOS presence in the cells are in the agreement on HL-60 cells where HNE
does not affect c-FOS [32], but inhibits c-MYC [33] indicating that this decrease can be the
cause of lower proliferation and viability at higher HNE concentrations. Interestingly,
c-MYC showed to be differently present in differentiated and undifferentiated HOS.
Overexpression of c-MYC increases proliferation of mesenchymal stem cells [34]. As c-
MYC is a transcription factor which activates genes involved in proliferation [35], this result
supports lower proliferation index in differentiated HOS.
One of the possible explanations of those results is that differentiated HOS probably
reached senescence. In support of this possibility is the data showing that senescent
chondrocytes are more sensitive to oxidative stress [36]. We expected that one of the factors
causing different sensitivity to HNE could be the changes in reduced glutathione (GSH)
level. GSH is an important intracellular protector against free radicals as well as radical
scavenger responsible for HNE detoxification [37].
The GSH content in differentiated and undifferentiated HOS was measured showing
that differentiated HOS cells had lower levels of GSH, which might explain their higher
sensitivity to HNE. Levels of oxidized GSH were below 10% in both nondifferentiated and
differentiated HOS cell cultures, showing that those cells were equally viable. The process
of HOS cells differentiation was associated with changes in cell metabolism resulting in
decreased GSH content in those cells. GSH content in cells is different depending on the
cell cycle: it increases from G phase through S phase and reaches maximum at G2/M
phase [38]. Differentiated osteosarcoma cells had lower number of mitotic cells, thereby
agreeing with this study. Some malignant cells like hepatoma have higher GSH than
normal hepatic cells [39], while nonmalignant mesenchymal cells have higher amounts of
GSH than osteosarcoma cells [14]. Differences in GSH content appear to play an important
role in cellular sensitivity to HNE.
Treatment with HNE additionally decreased GSH content in cells [37]. Lower content
of GSH and its consumption resulted in higher HNE-protein adducts in differentiated HOS
cells. Previously, we presented linear correlation between GSH content and HNE-protein
adducts formed in cells after exposure to HNE [14]. After a certain period of time, both GSH
level and HNE-protein adducts reached equilibrium, regardless of the free HNE in cell
supernatant and free GSH. In this equilibrium state GSH and HNE-protein adducts reached
plateau. One of the possibilities for these results is the method for measuring HNE-protein
adducts, which detects only HNE-histidine adducts, but not other modifications, such as
lysine, cysteine, or arginine [40]. HNE-protein adducts are formed in vivo in cancer cells
and normal tissue and change during tumor progression. Depending on tumor origin
and stage, formation of adducts could be lower, the same, and higher than corresponding
normal tissue [41,42].
HNE is a substrate of glutathione S-transferases (GST) [43], a family of enzymes
that catalyzes the conjugation of chemicals to glutathione. Two isozymes of α-class of
GSTs, hGSTA4-4 and hGST5.8 have high catalytic affinity for HNE [44,45]. GS-HNE con-
jugates are exported from the cells by active ATP-dependent transport through RLIP76
protein [46]. We measured total glutathione transferase activity in HOS and there was no
difference between differentiated and undifferentiated HOS. Overexpression of GSTs is
related to an increase in resistance to anticancer drugs or alkylating agents [47,48]. In ker-
atinocytes, HNE metabolites are determined by MS; 48% are attributed to two unconjugated
metabolites created by aldehyde dehydrogenase [49] and 52% are four metabolites created
by conjugation with GSH further metabolized by oxido-reductive enzymatic processes.
In erythrocytes, 70% of metabolites are conjugates with glutathione and 25% one of the
unconjugated metabolites [50]. It seems that cells of different origin differ in preference of
metabolic pathways which is used for HNE degradation. Earlier, we determined linear
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correlation between HNE-modified proteins and GSH content in mesenchymal cells [14],
so we supposed that these cells use GSH preferentially to eliminate HNE.
Proteasomes are responsible for degradation of damaged proteins and its role in tumor
progression is not yet clear although there are attempts to use proteasomal inhibitors in
tumor treatments [51]. HNE damages proteins which are then substrate for degradation
by 20S proteasome subunit of 26S proteasome, responsible also for degrading oxidized
proteins. Mildly modified proteins with HNE concentrations such as 1–10 µM are easily
degraded by the proteasome, while high concentrations of HNE such as 100 µM extensively
modify proteins. This results in formation of protein aggregates which inhibit proteasomal
activity [52]. Undifferentiated and differentiated HOS were checked for 26S proteasomal
activity and we found that differentiated HOS had lower proteasomal activity which makes
processing damaged proteins more problematic. HNE induced production of ROS in undif-
ferentiated and differentiated HOS after treatment in a concentration dependent manner,
the higher the HNE concentration used, the higher were the ROS levels measured. In sup-
port to GSH results, HNE caused higher increase of ROS in differentiated HOS. The method
we used for ROS determination with DCFH-DA is widely used for H2O2, although there
are some controversies about the compound which causes oxidation of this substrate. It is
suggested that hydroxy radicals or peroxinitrite could do that also [53]. Fatty acid compo-
sition in undifferentiated and differentiated HOS was measured because PUFAs can serve
as a substrate for oxidation. Only one fatty acid was found to be significantly different
between HOS with different degree of differentiation and this was 5,8,11-eicosatrienoic
acid (C20:3 n-9, mead acid) which was found to be higher in differentiated cells.
This particular fatty acid belongs to the group of omega-9 fatty acids and is the
only one formed de novo in the body in the state of fatty acid deficiency. Essential fatty
acid deficiency (EFAD) is considered when the ratio between triene/tetraene fatty acids
is >0.4 [54]. C20:3 is formed from oleic acid when there is restriction in omega-6 fatty
acids [55]. The elevated level of C20:3 in differentiated HOS cells could be due to increased
expression of enzymes involved in omega-9 fatty acid synthesis. Indeed, studies on NIH3T3
and Hepa1-6 cells demonstrated that Elovl5, Fads1, or Fads2 are involved in synthesis of
20:3 omega-9 fatty acid and their downregulation causes a decrease in C20:3 fatty acid
level [56]. Furthermore, EFAD changes composition of fatty acids in bone tissues toward
high C20:3 and low C20:4 [57]. Normal, young cartilage has very high content of C20:3
levels and low level of C20:4 [58]. This is supposed to be result of fatty acid deficiency due
to low vascularization, and C20:3 is also blocking angiogenesis [59]. However, data are not
straightforward because results in growing chicks show very high C20:4 in bone as well as
in cartilage, but not C20:3 [60]. Perhaps consummation of food with a higher amount of
omega-6 linoleic acid than omega-9 oleic acid causes this [60].
There are no literature data about the role of C20:3 fatty acid in cells of osteogenic origin
as well as osteosarcoma cells. It is known that it serves as a substrate for 5-lipooxigenase
and is converted into LTA3 which inhibits synthesis of proinflammatory LTB4 [61]. It is
supposed to block osteoblasts activity, decreasing ALP activity in osteoblasts [62]. In our
study differentiated HOS had both increased alkaline phosphatase activity and more C20:3,
therefore, our results do not support this. It is known that addition of other fatty acids
such as docosahexaenoic acid n-3 induces apoptosis via ROS production [63]; addition of
PUFAs can induce oxidative stress [64] because PUFAs can be autoxidized or enzymatically
oxidized by oxidases [65,66]. In our study differentiated HOS had more PUFAs in total,
which can increase their sensitivity to cytotoxic activity of HNE.
The differentiation of HOS was accompanied by a decrease in the ability of HOS cells
to metabolize HNE and protect themselves from its toxic effects. Since differentiation of
HOS cells was accompanied also by increased production of C20:3 fatty acid, we assume
that could make them more subjected to free radical-initiated oxidative chain reactions and
more vulnerable to the effects of reactive aldehydes such as HNE. In favor of this possibility
are findings of novel, selective anticancer effects of HNE observed for the other cancer cell
types [67], related to the lipid metabolism and ROS production by cancer and surrounding
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nonmalignant cells [68], resembling findings observed also for another reactive aldehyde
acrolein [69,70], thus supporting further studies on biomedical relevance of these bioactive
markers of lipid peroxidation [71,72].
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60. Dołȩgowska, B.; Machoy, Z.; Chlubek, D. Profiles of Fatty Acids in Different Bone Structures of Growing Chicks. Vet. Res. Commun.
2006, 30, 735–747. [CrossRef]
61. James, M.J.; Gibson, R.A.; Cleland, L.G. Dietary Polyunsaturated Fatty Acids and Inflammatory Mediator Production.
Am. J. Clin. Nutr. 2000, 71, 343s–348s. [CrossRef]
62. Hamazaki, T.; Suzuki, N.; Widyowati, R.; Miyahara, T.; Kadota, S.; Ochiai, H.; Hamazaki, K. The Depressive Effects of 5,8,11-
Eicosatrienoic Acid (20:3n-9) on Osteoblasts. Lipids 2009, 44, 97–102. [CrossRef]
63. Sung Kang, K.; Wang, P.; Yamabe, N.; Fukui, M.; Jay, T.; Ting Zhu, B. Docosahexaenoic Acid Induces Apoptosis in MCF-7 Cells In
Vitro and In Vivo via Reactive Oxygen Species Formation and Caspase 8 Activation. PLoS ONE 2010, 5, e10296. [CrossRef]
64. Guichardant, M.; Chen, P.; Liu, M.; Calzada, C.; Colas, R.; Véricel, E.; Lagarde, M. Functional Lipidomics of Oxidized Products
from Polyunsaturated Fatty Acids. Chem. Phys. Lipids 2011, 164, 544–548. [CrossRef] [PubMed]
65. Cosgrove, J.P.; Church, D.F.; Pryor, W.A. The Kinetics of the Autoxidation of Polyunsaturated Fatty Acids. Lipids 1987, 22, 299–304.
[CrossRef] [PubMed]
66. Astarita, G.; Kendall, A.C.; Dennis, E.A.; Nicolaou, A. Targeted Lipidomic Strategies for Oxygenated Metabolites of Polyunsatu-
rated Fatty Acids. Biochim. Biophys. Acta-Mol. Cell Biol. Lipids 2015, 1851, 456–468. [CrossRef] [PubMed]
67. Bauer, G.; Zarkovic, N. Revealing mechanisms of selective, concentration-dependent potentials of 4-hydroxy-2-nonenal to induce
apoptosis in cancer cells through inactivation of membrane-associated catalase. Free Radic. Biol. Med. 2015, 81, 128–144. [CrossRef]
[PubMed]
68. Zhong, H.; Xiao, M.; Zarkovic, K.; Zhu, M.; Sa, R.; Lu, J.; Tao, Y.; Chen, Q.; Xia, L.; Cheng, S.; et al. Mitochondrial Control of
Apoptosis through Modulation of Cardiolipin Oxidation in Hepatocellular Carcinoma: A Novel Link between Oxidative Stress
and Cancer. Free Radic. Biol. Med. 2015, 176, 67–76. [CrossRef] [PubMed]
Cells 2021, 10, 269 20 of 20
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